Arrow International, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.5Mgeneral payments (2019-2025)
$70Kresearch payments (2019-2025)
203clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Arrow $434K associated (2023-2025)
- Manta $112K associated (2023-2025)
- Guideliner $48K associated (2023-2025)
- Turnpike $20K associated (2023-2025)
- Lma Airway Management $8,376 associated (2023-2025)
- Deknatel $6,156 associated (2023-2025)
- Titan Sgs $4,950 associated (2023-2025)
- Oncontrol Powered Driver $30.88 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Timothy Clark | Philadelphia, PA | Vascular & Interventional Radiology | $518,512.08 |
| Scott Trerotola | Philadelphia, PA | Vascular & Interventional Radiology | $334,386.94 |
| Andre Boezaart | Gainesville, FL | Anesthesiology | $119,376.81 |
| Siddharth Wayangankar | Jacksonville, FL | Interventional Cardiology | $65,102.38 |
| John Ross | Orangeburg, SC | Vascular Surgery | $49,303.49 |
| David Berman | St Petersburg, FL | Pediatric Infectious Diseases | $48,003.90 |
| Joan Pehta | New Canaan, CT | Blood Banking & Transfusion Medicine | $36,305.00 |
| Rhian Davies | York, PA | Cardiovascular Disease | $29,518.89 |
| Kevin Croce | Chestnut Hill, MA | Cardiovascular Disease | $22,209.73 |
| Jacob Keeperman | Saint Louis, MO | Critical Care Medicine (Anesthesiology) | $20,287.36 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.